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a b s t r a c t
The mechanism of amiloride inhibition of Coxsackievirus B3 (CVB3) and poliovirus type 1 (PV1) RNA
replication was investigated using membrane-associated RNA replication complexes. Amiloride was
shown to inhibit viral RNA replication and VPgpUpU synthesis. However, the drug had no effect on
polymerase elongation activity during either () strand or (þ) strand synthesis. These ﬁndings
indicated that amiloride inhibited the initiation of RNA synthesis by inhibiting VPg uridylylation.
In addition, in silico binding studies showed that amiloride docks in the VPg binding site on the back of
the viral RNA polymerase, 3Dpol. Since VPg binding at this site on PV1 3Dpol was previously shown to be
required for VPg uridylylation, our results suggest that amiloride inhibits VPg binding to 3Dpol.
In summary, our ﬁndings are consistent with a model in which amiloride inhibits VPgpUpU synthesis
and viral RNA replication by competing with VPg for binding to 3Dpol.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Coxsackievirus B3 (CVB3) and poliovirus type 1 (PV1) are
human enteroviruses that belong to the Picornaviridae family of
(þ) strand RNA viruses. The 50 end of the single-stranded RNA
genome is covalently linked to a virus-encoded protein, VPg, and
the 30 end is polyadenylated. The genomic RNA contains a large
open reading frame ﬂanked by 50 and 30 nontranslated regions
(NTRs). Translation of the viral genome results in the synthesis of a
polyprotein, which is processed by viral proteases 2Apro and 3Cpro/
3CDpro into the mature viral proteins. The P1 region of the genome
encodes the capsid proteins, and the P2 and P3 regions encode the
non-structural proteins that are required for RNA replication
including 3Dpol, the viral RNA-dependent RNA polymerase.
The 50 terminal cloverleaf (50CL), the 30NTR including the poly
(A) tail and the internal cre(2C) hairpin are cis-acting elements
that are needed for viral RNA replication (Liu et al., 2009; Steil and
Barton, 2009a; Ogram and Flanegan, 2011). The 50CL is a multi-
functional element that is required for translation, () and (þ)
strand synthesis and VPg uridylylation (Barton et al., 2001;
Gamarnik and Andino, 1998, 2000; Murray et al., 2001;
Ogram et al., 2010; Sharma et al., 2005, 2009; Spear et al., 2008;
Teterina et al., 2001; Vogt and Andino, 2010). The conserved cre
hairpin structure in the 2C coding region of the RNA genome
serves as the primary template for VPg uridylylation by 3Dpol to
form VPgpUpU (McKnight and Lemon, 1998; Goodfellow et al.,
2000; Paul et al., 2000; Gerber et al., 2001). Results of many
studies show that VPgpUpU serves as the primer for 3Dpol to
initiate both () and (þ) strand synthesis (Fogg et al., 2003;
Morasco et al., 2003; Murray and Barton, 2003; Takegami et al.,
1983a, 1983b; Toyoda et al., 1987; Steil and Barton, 2009b; van
Ooij et al., 2006).
The drug, amiloride, was previously shown to inhibit CVB3
replication in infected HeLa cells by inhibiting viral RNA replica-
tion without affecting host or viral protein synthesis (Harrison
et al., 2008). Amiloride was also shown to increase the mutation
frequencies of both CVB3 and PV1 in infected cells. This was
shown to be an indirect mutagenic effect that was mediated by an
increase in the intracellular concentration of Mg2þ and Mn2þ ,
which affected the ﬁdelity of the viral polymerase (Levi et al.,
2010). The effect of amiloride on single-nucleotide (AMP) incor-
poration was investigated in assays containing puriﬁed CVB3 3Dpol
and a 10-nucleotide, self-annealing, RNA primer-template (SSU)
(Gazina et al., 2011). A small inhibitory effect on nucleotide
incorporation (o9%) was observed in these reactions when
amiloride was added with ATP in the presence of Mg2þ . Effective
inhibition was only observed when 3Dpol was preincubated with
amiloride for several minutes in the absence of ATP or Mg2þ .
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Taken together, these results indicate that the kinetics of amiloride
inhibition of 3Dpol catalytic activity is very slow compared to the
rapid rate of ATP incorporation in the presence of Mg2þ . Finally,
amiloride was shown to inhibit VPgpUpU synthesis in reconsti-
tuted reactions containing puriﬁed CVB3 3Dpol, VPg and cre hair-
pin RNA (Gazina et al., 2011). Interestingly, the inhibition of
VPgpUpU synthesis by amiloride was not dependent on preincu-
bating 3Dpol with the drug prior to adding UTP to start the
reaction.
In the current study, we examined the effect of amiloride on
CVB3 and PV1 RNA replication in preinitiation replication com-
plexes (PIRCs) isolated from HeLa cell-free reactions (Barton and
Flanegan, 1997; Lyons et al., 2001; Morasco et al., 2003; Sharma
et al., 2009). Our ﬁndings showed that amiloride had no measur-
able effect on the elongation activity of the viral polymerase, but
speciﬁcally inhibited the initiation of RNA replication and VPg
uridylylation. Furthermore, in silico binding studies showed that
amiloride docks at the VPg binding site previously identiﬁed at the
back of 3Dpol. Since previous genetic studies indicate that VPg
binding to this site is required for efﬁcient VPgpUpU synthesis
(Lyle et al., 2002), our results suggest that amiloride inhibits VPg
binding to 3Dpol. Based on these ﬁndings, we propose a model in
which amiloride competes with VPg for binding to the site on the
back of 3Dpol, which in turn inhibits VPgpUpU synthesis and viral
RNA replication.
Results
Effect of amiloride on viral RNA replication.
To investigate the underlying mechanism of amiloride inhibi-
tion of CVB3 RNA replication, we used membrane-associated
preinitiation replication complexes (PIRCs) isolated from HeLa
S10 reactions. In previous studies, we showed that PIRCs support
efﬁcient VPgpUpU synthesis and () and (þ) strand synthesis
(Sharma et al., 2009). CVB3 P23 RNA is a subgenomic RNA that
contains sequences for the 50NTR, the P23 coding region that
encodes the replication proteins, the 30NTR and poly(A) tail. P23
RNA contains two non-viral G residues at the 50 end which
supports only () strand RNA synthesis. This RNA was added to
HeLa S10 reactions, and PIRCs were isolated from the reactions at
3 h. The PIRCs were resuspended in replication assay buffer
containing all four NTPs, [α-32P] CTP and Mg2þ . Labeled ()
strand synthesis was measured in the presence or absence of
amiloride as described in Materials and methods. The amount of
labeled () strand RNA synthesized in each reaction was deter-
mined by electrophoresis in a denaturing agarose gel. In the
presence of 0.4, 0.8 and 1.6 mM amiloride, () strand synthesis
was 49%, 25% and 2%, respectively of the level observed in the
absence of the drug (Fig. 1A). The concentration of amiloride
required to observe 50% inhibition of () strand synthesis (IC50)
was calculated and shown to be 0.41 mM in these reactions
(Fig. 1B). These results demonstrated that amiloride inhibited
() strand synthesis in a concentration dependent manner
in PIRCs.
Since amiloride inhibited CVB3 () strand synthesis, a corre-
sponding decrease in (þ) strand synthesis should also be observed
in the presence of the drug. To determine if amiloride differentially
inhibited CVB3 (þ) strand synthesis, we measured the effect of
amiloride on the ratio of (þ)/() strand synthesis (Sharma et al.,
2009). A decrease in the (þ)/() strand ratio should be observed if
amiloride differentially inhibits (þ) strand synthesis. The (þ)/()
strand ratio was calculated by measuring labeled RNA synthesis in
reactions containing CVB3 P23 RNA or CVB3 RzP23 RNA as
previously described (Sharma et al., 2009). () strand RNA is
synthesized in reactions containing P23 RNA. In contrast, both ()
strand and (þ) strand RNAs are synthesized in reactions contain-
ing RzP23 RNA. This RNA contains a 50 hammerhead ribozyme (Rz)
which upon cleavage generates an authentic 50 terminus which
supports both () and (þ) strand synthesis. The effect of amilor-
ide on labeled RNA synthesis was determined in separate reactions
containing either P23 or RzP23 RNA. The results showed that
amiloride inhibited () strand synthesis (Fig. 1C left) and overall
synthesis (both (þ) and () strands) (Fig. 1C right) by similar
amounts. The amount of labeled RNA synthesized in each reaction
was then used to calculate the ratio of (þ)/() strand synthesis as
described in Materials and methods. In the absence of the drug, the
(þ)/() strand ratio was 14 consistent with the previous studies
(Fig. 1C) (Sharma et al., 2009). In reactions containing 0.4 mM and
0.8 mM amiloride, the (þ)/() strand ratio was 14 and 10,
respectively (Fig. 1C). These results indicated that amiloride had
no signiﬁcant effect on the ratio of (þ)/() strand synthesis and
therefore, amiloride did not differentially inhibit CVB3 (þ) strand
synthesis.
We next determined if amiloride also inhibited PV1 RNA
replication in PIRCs. The synthesis of () strand RNA was mea-
sured in the presence or absence of amiloride as described above.
In the presence of 0.4, 0.8 and 1.6 mM amiloride, () strand
synthesis was 58%, 28% and 2%, respectively, of the level observed
in the absence of the drug (IC50¼0.48 mM) (Fig. 2A and B). These
results showed that amiloride inhibited PV1 () strand synthesis
at levels similar to that observed with CVB3 P23 RNA (Fig. 1A).
To determine the effect of amiloride on (þ) strand synthesis in
reactions containing PV1 RNA, we calculated the (þ)/() strand
ratio by measuring labeled RNA synthesis in reactions containing
PV1 P23 RNA or PV1 RzP23 RNA. Amiloride inhibition of ()
strand synthesis (Fig. 2C left) and overall synthesis (Fig. 2C right)
was similar in these reactions. The ratio of (þ)/() strand
synthesis was 20 in the absence of the drug (Fig. 2C). In reactions
containing 0.4 mM or 0.8 mM amiloride, the (þ)/() strand ratio
was 18 and 23, respectively (Fig. 2C). As previously observed with
CVB3, amiloride had no signiﬁcant effect on the ratio of (þ)/()
strand synthesis during PV1 RNA replication and did not differen-
tially inhibit (þ) strand synthesis.
Effect of amiloride on () strand elongation
We next investigated if amiloride inhibited the elongation of
CVB3 () strand RNA in replication complexes. To do this, we
measured the effect of amiloride on the time required to synthe-
size full-length () strand RNA in PIRCs. In these reactions,
removal of guanidine–HCl allows for the synchronous initiation
of () strand synthesis. If amiloride inhibits the elongation rate of
3Dpol, then the time required to synthesize full-length () strand
RNA will increase in the presence of the drug. In contrast, if
amiloride inhibits the initiation of RNA synthesis, the total amount
of RNA synthesized will decrease but the time required to
synthesize full-length RNA will be the same. PIRCs were isolated
from reactions containing CVB3 P23 RNA and resuspended in
replication buffer in the presence or absence of amiloride. Aliquots
were removed at the indicated times and labeled product RNA was
analyzed by denaturing agarose gel electrophoresis. In the
untreated reactions, the growing nascent RNA chains were
observed at 5, 6 and 7 min and full-length () strand RNA was
observed at 8 min (Fig. 3A). In the presence of 0.8 mM amiloride,
full-length () strand RNA was detected at 8–9 min although the
overall intensity of the product RNA was signiﬁcantly reduced
(Fig. 3A). These results indicated that amiloride had no signiﬁcant
effect on the time required to synthesize full-length product RNA
even though the overall level of () strand synthesis was inhibited
by four-fold (Fig. 1A). Taken together, these results indicated that
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amiloride inhibited CVB3 () strand initiation but had little effect
on polymerase elongation activity.
To examine if amiloride inhibited RNA elongation during PV1
() strand RNA synthesis a similar time-course experiment was
performed using PIRCs containing PV1 P23 RNA. The growing
nascent RNAs were observed between 5 and 8 min and full-length
() strand RNA was observed at 8 min in the untreated reactions
(Fig. 3B). In the presence of 0.8 mM amiloride, full-length ()
strand RNA was again detected at 8 min, although the overall level
of () strand synthesis was signiﬁcantly reduced by the drug
(Fig. 3B). Since amiloride had no signiﬁcant effect on the time
required to synthesize full-length () strand RNA, we concluded
that amiloride inhibited PV1 () strand initiation but had no
signiﬁcant effect on nascent chain elongation.
Effect of amiloride on (þ) strand elongation
The effect of amiloride on the elongation of nascent (þ) strand
RNA in replication complexes was also investigated. To do this,
preformed RNA replication complexes were isolated from reactions
Fig. 1. Effect of amiloride on CVB3 RNA replication and the ratio of (þ)/() strand synthesis. (A) () strand synthesis is measured in PIRCs containing CVB3 P23 RNA, which
supports only () strand synthesis. PIRCs are resuspended in replication assay buffer containing [α-32P]CTP in the presence of increasing concentrations of amiloride and the
reactions are incubated at 37 1C for 1 h. The labeled product RNAs are analyzed by electrophoresis in a denaturing CH3HgOH–agarose gel visualized by autoradiography and
quantitated using a PhosphorImager. (B) The effect of amiloride on () strand synthesis is plotted as a function of amiloride concentration. These results are used to calculate
the 50% inhibitory concentration (IC50) of amiloride as described in Materials and methods. (C) The replication of CVB3 P23 RNA or CVB3 RzP23 RNA is measured in reactions
containing increasing concentrations of amiloride. () strand synthesis is measured in reactions containing CVB3 P23 RNA, and () and (þ) strand synthesis is measured in
reactions containing CVB3 RzP23 RNA. The labeled product RNAs are analyzed by denaturing agarose gel electrophoresis during which the RNA structure is completely
disrupted, including RI and RF RNAs. The ratio of (þ)/() strand synthesis is calculated as described in Materials and methods.
Fig. 2. Effect of amiloride on PV1 RNA replication and the ratio of (þ)/() strand synthesis. (A) The effect of amiloride on PV1 () strand synthesis is measured in PIRCs
containing PV1 P23 RNA as described in Fig. 1A. (B) The IC50 for amiloride inhibition of PV1 () strand synthesis is determined as described in Fig. 1B. (C) The replication of
PV1 P23 RNA or PV1 RzP23 RNA is measured in reactions containing increasing concentrations of amiloride. RNA replication and the ratio of (þ)/() strand RNA synthesis
are determined as described in Fig. 1C.
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containing RzP23 RNA. The preformed replication complexes con-
tain replication intermediate RNA, which consists of a () strand
template and multiple nascent (þ) strands (Fig. 4A). RNA replica-
tion assays were then performed in the presence or absence of
amiloride. In these assays, the preformed nascent (þ) strands were
allowed to elongate into full-length (þ) strand RNA in the presence
of [α-32P] CTP (Fig. 4B). The reactions were incubated for a total of
5 min and aliquots were removed at the indicated time points
(Fig. 4B). The 5 min incubation period was long enough to allow
most of the nascent (þ) strands to elongate into full-length RNA but
was too short to allow for the re-initiation and synthesis of full-
length RNA. Therefore, only elongation of preformed nascent (þ)
strands into full-length (þ) strand RNA was measured in these
reactions. The amount of full-length labeled RNA synthesized at
each time point was quantitated and expressed as PI units in the bar
graph shown below the gel panel. As expected, the amount of full-
length RNA increased as a function of incubation time (Fig. 4B).
If amiloride inhibited the elongation of nascent chains, the amount
of labeled full-length RNA synthesized at each time point would be
lower in the presence of the drug. However, there was no signiﬁcant
difference in the amount of labeled RNA synthesized at each time
point in the absence or presence of the drug (Fig. 4B). The average
incorporation rate of [32P] CMP into (þ) strand RNA was 1.970.5
and 2.170.7 PI units/min, in the absence or presence of amiloride,
respectively. These results clearly demonstrated that amiloride did
not inhibit the elongation of CVB3 (þ) strand RNA in replication
complexes.
Using the same experimental approach, the effect of amiloride
on the elongation of nascent PV1 (þ) strand RNA was also
investigated. Once again, the amount of labeled full-length RNA
increased as a function of incubation time, and there was no
signiﬁcant difference in the amount of labeled RNA synthesized at
each time point in the absence or presence of amiloride (Fig. 4C).
The average incorporation rate of [32P] CMP into (þ) strand RNA
was 2.170.7 and 2.370.5 PI units/min in the absence or presence
of amiloride, respectively. Based on these results, we concluded
that amiloride did not inhibit the elongation of PV1 (þ) strand
RNA. Taken together, the above results conﬁrmed that amiloride
did not signiﬁcantly inhibit the elongation activity of either CVB3
or PV1 3Dpol in replication complexes.
Effect of amiloride on cre-dependent VPgpUpU synthesis
The above results demonstrated that amiloride inhibited RNA
replication but did not inhibit the elongation activity of 3Dpol.
Therefore, these ﬁndings suggested that amiloride inhibited the
initiation of () and (þ) strand synthesis during RNA replication.
Since uridylylation of VPg is required for the initiation of () and
(þ) strand synthesis, we investigated the effect of amiloride on
cre-dependent VPgpUpU synthesis in PIRCs. To measure cre-
dependent VPgpUpU synthesis, PIRCs were isolated from reactions
containing CVB3 P23 RNA. The indicated concentrations of amilor-
ide were added to the reactions and VPg uridylylation assays were
performed as described in Materials and methods. VPgpUpU
synthesis was inhibited by amiloride in a concentration dependent
manner with an IC50 of 0.37 mM (Fig. 5A). We also examined if
amiloride inhibited cre-dependent VPgpUpU synthesis in reactions
containing PV1 P23 RNA. Once again, VPgpUpU synthesis was
inhibited by amiloride in a concentration dependent manner with
an IC50 of 0.67 mM (Fig. 5B). Taken together these ﬁndings
demonstrated that amiloride inhibited cre-dependent VPgpUpU
synthesis in replication complexes containing CVB3 or PV1 RNA.
Molecular docking analysis of VPg-3Dpol and amiloride-3Dpol
interactions
A previous study identiﬁed a VPg binding site in the back of the
thumb region of 3Dpol in the CVB3 VPg-3Dpol crystal structure
(Gruez et al., 2008). In this co-crystal structure, residues 7–15 of
VPg were observed to bind along the back of the thumb region of
CVB3 3Dpol (PDB: 3CDW) (Gruez et al., 2008). To generate a full-
length model of VPg binding to this site in CVB3 and PV1 3Dpol, we
performed molecular docking studies based on the published
CVB3 VPg-3Dpol co-crystal structure. Using the known sequences
for both CVB3 and PV1 VPg, the fragmented crystallographic
model was extended bilaterally with subsequent rounds of simu-
lated annealing for energy minimization and potential electro-
static interaction developments in DeepView (Guex and Peitsch,
1997). The models showing the interaction of the full-length VPg
with the VPg binding site on the back of CVB3 and PV1 3Dpol are
shown in Figs. 6A and 7A, respectively.
In both models, we observed that the tyrosine (Y3), which is
the UMP-linkage site in the N-terminus of VPg, was distal from the
nucleotide entry channel (Figs. 6A and 7A). Furthermore, residues
R380 and E383 of CVB3 3Dpol and R379 and E382 of PV1 3Dpol
were seen to make hydrogen bond connections to several side-
and main-chain atoms in VPg (Figs. 6B and 7B). The guanidine
group of R380 hydrogen bonds to the carbonyl groups of V13 and
P14 of VPg; the carboxylate of E383 hydrogen bonds with Q9 of
VPg (Fig. 6B). In the full-length model of CVB3 and PV1 VPg, there
are other interactions sites between 3Dpol and VPg that can offer
further binding stability (Tables 1 and 2). There are some minor
local differences in VPg binding when comparing CVB3 to PV1
(Tables 1 and 2) such as the binding motifs for K10 and R17 on the
two polymerases but the overall interaction domains are similar
(compare cyan colors in Figs. 6A and 7A).
The interaction energy of VPg binding to the back of 3Dpol was
calculated via PDBePISA (Table 3) (Krissinel and Henrick, 2007).
The higher binding energy observed with PV1 is in accordance
with the increased number of hydrogen bonds and van der Waals
interactions seen to be occurring between PV1 3Dpol and VPg
compared to CVB3 3Dpol and VPg (Tables 1 and 2). For example, it
can be seen that PV1 3Dpol presents several more hydrogen
bonding partners to PV1 VPg residues N8, K9, K10 and R17 than
Fig. 3. Effect of amiloride on () strand elongation in CVB3 and PV1 RNA
replication complexes. (A) To measure CVB3 () strand elongation, PIRCs contain-
ing CVB3 P23 RNA are resuspended in replication assay buffer in the presence or
absence of 0.8 mM amiloride. The reactions are incubated at 37 1C and aliquots are
removed at the indicated time points. The labeled product RNAs are analyzed by
denaturing agarose gel electrophoresis as described in Materials and methods. The
gel panel on the right which contained labeled RNA synthesized in the presence of
amiloride is exposed about 5-times longer than the gel panel on the left. (B) PV1
() strand RNA elongation is measured as described in (A).
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the comparable residues in CVB3 VPg that interacted with 3Dpol.
Based on the calculated binding energies for VPg and 3Dpol, it
appears that PV1 VPg binds with a 2.3 fold higher afﬁnity to PV1
3Dpol compared to the binding of CVB3 VPg to CVB3 3Dpol.
Molecular docking studies were also performed to determine if
amiloride docked in the VPg binding site on the back of 3Dpol as
well as in the catalytic site of 3Dpol. Our results showed that
amiloride did not dock in the catalytic site of 3Dpol in the presence
of Mg2þ , which was in agreement with the molecular docking
results of a previous study (Gazina et al., 2011). This ﬁnding was
consistent with our results which showed that amiloride did not
inhibit the catalytic activity of 3Dpol in RNA elongation assays.
Importantly, our docking results revealed two potential binding
pockets for amiloride (‘A’ and ‘B’) within the VPg binding site
(Figs. 6A and C; 7A and C). These two sites gave the tightest
binding energies (i.e. more negative solvation energy) along the
entire surface of the VPg binding channel and resulted in the
docking of amiloride in these two sites in every docking attempt.
Therefore, no other binding sites were identiﬁed in the search
area. The docking energies were calculated using the webserver
PEARLS (Han et al., 2006) and were 5 kcal mol1 at the two sites
(Table 3). The calculated binding afﬁnities for amiloride binding to
both CVB3 and PV1 3Dpol were essentially the same. Our docking
study showed that amiloride made several H-bonds and van der
Waals interactions with 3Dpol in sites ‘A’ and ‘B’ (Tables 1 and 2).
Interestingly, there are several conserved residues in 3Dpol that
interact with both amiloride and VPg (Tables 1 and 2; yellow
residues in Figs. 6A and 7A). The presence of two potential
amiloride binding sites on 3Dpol may increase the ability of
amiloride to inhibit VPg binding to 3Dpol. Taken together, these
results suggest that amiloride competes with VPg for binding at
the same site in the polymerase.
Discussion
In this study, we used membrane-associated replication com-
plexes containing viral RNA to investigate the underlying mechan-
ism of amiloride inhibition of CVB3 RNA replication. These
complexes allowed us to independently analyze the effect of the
drug on () and (þ) strand synthesis as well as VPgpUpU
synthesis. Furthermore, we were able to separately investigate
the effect of amiloride on the initiation and elongation of RNA
synthesis. Our results showed that amiloride inhibited overall
CVB3 RNA replication without inhibiting the elongation activity
of the viral polymerase. These results suggested that amiloride
inhibited RNA replication at the initiation step. Consistent with
this conclusion was our ﬁnding that amiloride inhibited the
synthesis of VPgpUpU, the primer used by the viral polymerase
to initiate RNA synthesis. In this study, we also investigated the
Fig. 4. Effect of amiloride on elongation of (þ) strand RNA in preformed replication complexes containing CVB3 or PV1 RNA. (A) Schematic representation of the elongation
of nascent (þ) strand RNA in replicative-intermediate (RI) RNA that is present in preformed replication complexes. (B) To measure (þ) strand elongation, preformed
replication complexes containing CVB3 RzP23 RNA are resuspended in replication assay buffer in the presence or absence of 0.8 mM amiloride as described in Materials and
methods. The reactions are incubated at 37 1C and aliquots are removed at the indicated time points. The labeled product RNAs are analyzed by denaturing agarose gel
electrophoresis. The amount of labeled product RNA synthesized at each time point is quantitated as PhosphorImager units (PI units) and is shown as a bar graph below the
gel panel. (C) PV1 (þ) strand RNA elongation is measured as described in (B).
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effect of amiloride on the replication of poliovirus (PV1). Amiloride
inhibited the overall replication of PV1 RNA but did not inhibit the
polymerase elongation activity. In addition, amiloride inhibited
VPgpUpU synthesis in reactions containing PV1 RNA. Taken
together, these ﬁndings are consistent with a model in which
amiloride inhibited the initiation of both CVB3 and PV1 RNA
replication by inhibiting VPgpUpU synthesis.
We showed that amiloride inhibited () strand RNA synthesis
in reactions containing CVB3 and PV1 P23 RNA transcripts, which
supported only one round of () strand synthesis. Furthermore,
overall RNA replication, which includes both () and (þ) strand
synthesis was also inhibited by amiloride. However, amiloride did
not affect the ratio of (þ)/() strand RNA synthesis, which
indicated that amiloride did not differentially inhibit (þ) strand
synthesis. Therefore, amiloride inhibited RNA replication for both
viruses and there was no signiﬁcant difference in the observed IC50
values determined in our assays. In a previous study by Harrison
et al. (2008), lower IC50 values for amiloride inhibition of CVB3
virus production were observed in cells infected at a low multi-
plicity of infection. In this case, however, the effect of the drug on
virus production was measured during multiple rounds of replica-
tion over a period of 48 h. Therefore, the experimental conditions
were very different in the two studies which would have affected
the IC50 values determined.
We next asked the question at what step did amiloride inhibit
RNA synthesis. Is it at the level of RNA elongation or RNA
initiation? Given that PIRCs can be used to follow initiation and
elongation of () strand RNA, we used this approach and showed
that the time taken to make full-length () strand RNA was
about the same in the presence or absence of amiloride. On the
other hand, the overall amount of product RNA was reduced in
the reactions containing amiloride. Based on these results, we
concluded that amiloride did not signiﬁcantly inhibit the elonga-
tion of () strand RNA during CVB3 or PV1 RNA replication even
though the total amount of RNA synthesized was reduced. We also
measured the effect of amiloride on the elongation of nascent (þ)
strand RNA in normal replication complexes containing either
CVB3 or PV1 RNA. If the elongation of nascent (þ) strand RNA was
inhibited by amiloride then the amount of labeled full-length
product RNA synthesized at each time point would be lower in the
presence of the drug. Interestingly, the rate of elongation of
labeled (þ) strand RNA synthesized was equivalent in the pre-
sence and absence of the drug. Taken together, our ﬁndings
demonstrated that amiloride did not signiﬁcantly inhibit the
elongation of either () or (þ) strand RNA in replication com-
plexes containing viral RNA and replication proteins.
Our ﬁnding that amiloride inhibited RNA synthesis but did not
inhibit the elongation activity of the viral polymerase raised the
possibility that amiloride inhibited RNA replication by inhibiting
the initiation step of RNA replication. The ﬁrst step in enteroviral
RNA replication is the synthesis of VPgpUpU, which is the primer
used to initiate viral RNA synthesis. In the absence of VPgpUpU,
initiation of both () and (þ) RNA synthesis will be inhibited. Our
results showed that amiloride inhibited both CVB3 and PV1
VPgpUpU synthesis in a concentration-dependent manner in the
membrane-associated replication complexes. Based on these ﬁnd-
ings, we concluded that amiloride inhibited the initiation of RNA
synthesis by inhibiting the synthesis of VPgpUpU during CVB3 and
PV1 RNA replication.
In structural studies with CVB3 3Dpol and VPg, a VPg binding
site in the base of the thumb region at the back of 3Dpol was
identiﬁed in the VPg-3Dpol co-crystal structure (Gruez et al., 2008).
Using the co-crystal structure and a molecular docking analysis,
we developed models which showed the interaction of full-length
Fig. 5. Effect of amiloride on CVB3 and PV1 cre-dependent VPgpUpU synthesis. (A) To measure VPgpUpU synthesis, PIRCs containing CVB3 P23 RNA are resuspended in
reaction mixtures containing [α-32P]UTP in the presence of increasing concentrations of amiloride. The reactions are incubated at 37 1C for 1 h. The labeled VPgpUpU
synthesized is analyzed by SDS-PAGE (9–18% polyacrylamide), detected by autoradiography and quantitated using a PhosphorImager. The effect of amiloride on VPgpUpU
synthesis is plotted as a function of amiloride concentration in the graph on the right. These results are used to calculate the IC50 for amiloride inhibition of CVB3 VPgpUpU
synthesis. (B) The inhibition of PV1 VPgpUpU synthesis by amiloride and the calculation of the IC50 is determined as described in (A).
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VPg with the VPg binding site on the back of CVB3 and PV1 3Dpol
(Figs. 6A and 7A). In this model, the UMP-linkage site in VPg, Y3, is
shown to be remote from the nucleotide entry site and the
catalytic site of the carrier 3Dpol (Figs. 6A and 7A). This suggests
that the VPg bound at this site in 3Dpol cannot be uridylylated by
the carrier 3Dpol, which raises the possibility of an intermolecular
uridylylation reaction in which two molecules of 3Dpol are
required for VPgpUpU synthesis (Tellez et al., 2006;Gruez et al.,
2008). In recent studies using EV-71, a similar model for inter-
molecular uridylylation has been proposed (Chen et al., 2013; Sun
et al., 2012). In earlier studies, mutations in the VPg binding site on
the back of PV1 3Dpol were shown to inhibit 3AB binding to 3Dpol
(Hope et al., 1997; Lyle et al., 2002). These mutations were also
shown to inhibit VPgpUpU synthesis in reconstituted assays with-
out inhibiting polymerase elongation activity (Lyle et al., 2002;
Boerner et al., 2005). These ﬁndings together with the co-crystal
structure suggested that VPg binding to this site plays an impor-
tant role during VPgpUpU synthesis.
Since our results demonstrated that amiloride inhibited
VPgpUpU synthesis without inhibiting the catalytic activity of 3Dpol,
it raised the possibility that amiloride inhibits VPg binding to the
site on the back of 3Dpol and thereby inhibits VPgpUpU synthesis.
To address this question, we used a molecular docking analysis to
show that two potential binding sites for amiloride are located in
the VPg binding site in both CVB3 and PV1 3Dpol. The calculated
energies for amiloride binding at the two sites in 3Dpol were similar
for both CVB3 and PV1 (Table 3). The docking analysis predicted
that several amino acids in 3Dpol interact with both amiloride and
VPg. This suggests that the amiloride binding sites overlap with the
VPg binding site in 3Dpol (Tables 1 and 2). This ﬁnding appears to be
analogous to the competitive inhibition of VPg uridylylation by 3AB
in reconstituted assays, which was attributed to 3AB and VPg
having overlapping binding sites on 3Dpol (Boerner et al., 2005).
The presence of two putative amiloride binding sites that overlap
with the VPg binding site on 3Dpol would be expected to increase
the ability of amiloride to compete with VPg for binding to 3Dpol
and inhibit VPg uridylylation. This would also provide an explana-
tion for how amiloride inhibits VPgpUpU synthesis without inhibit-
ing polymerase elongation activity.
In a previous study, an amiloride resistance mutation, A372V, in
3Dpol was identiﬁed in CVB3 infected cells (Harrison et al., 2008).
This mutation was also shown to increase the ﬁdelity of CVB3
3Dpol. It was proposed that the increase in ﬁdelity might con-
tribute to drug resistance by reducing the indirect mutagenic
effect of amiloride (Levi et al., 2010). Interestingly, the A372
residue in CVB3 3Dpol is located close to amino acids, W369 and
T370, which interact with VPg and amiloride in our docking
models (Fig. 6 and Table 1). Although, a direct interaction of
A372 with either amiloride or VPg was not observed in our
docking model, it is possible that the A372V mutation alters the
Fig. 6. Docking interactions of CVB3 3Dpol with full-length VPg and amiloride. (A) A surface representation of 3Dpol is shown in light gray. VPg and amiloride are shown in
green cartoon view and orange stick view, respectively. The sites in 3Dpol that correspond to the VPg interacting residues are colored cyan and the amiloride interacting sites
are colored light orange. The sites that are common for both ligands are colored pale yellow. The two amiloride binding sites in 3Dpol are labeled ‘A’ and ‘B’. The UMP-linkage
site, Y3, in the N-terminus of VPg is also shown in stick view. (B) Model showing hydrogen bond interactions (dashed black lines) between VPg (green Cα) and 3Dpol (light
gray Cα). The UMP-linkage site, Y3, and amino acid side chains involved in hydrogen bond interactions are also shown in the model. (C) Model showing the hydrogen bond
interactions between amiloride (orange) and 3Dpol (light gray Cα). ‘A’ and ‘B’ are the two amiloride binding sites in 3Dpol. Nitrogen atoms are colored in blue, oxygen in red,
chlorine in green and hydrogen in white. The speciﬁc hydrogen bond interactions shown in panels B and C are listed in Table 1. See Supplementary materials for PDB ﬁles of
these ﬁgures.
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structure of the amiloride and/or VPg binding sites and contributes
to the mechanism of amiloride resistance.
In summary, our results showed that amiloride inhibited CVB3
and PV1 RNA replication by inhibiting the synthesis of VPgpUpU,
the primer used by 3Dpol to initiate viral RNA replication. Using the
molecular docking analysis, we found two putative binding sites
for amiloride that overlapped with the VPg binding site on the
back of the viral polymerase. Based on these ﬁndings, we proposed
a model in which amiloride inhibits CVB3 and PV1 VPgpUpU
synthesis by competing with VPg for binding to 3Dpol. Importantly,
these results support the functional importance of the VPg binding
site on the back of 3Dpol during VPgpUpU synthesis and provide
new insights into the mechanism of VPg uridylylation. In addition,
the results of this study show that amiloride can be used as a
prototype to develop new drugs that target the VPg binding site on
the polymerase and speciﬁcally inhibit VPg uridylylation and viral
RNA replication.
Materials and methods
Coxsackievirus (CVB3) cDNA clones
The cDNA clone of Coxsackievirus B3 (CVB3) strain 28 was the
parental cDNA clone used to construct the plasmids used in this
study (Tracy et al., 2002). CVB3 derived plasmids pP23 and pRzP23
used in this study have been previously described (Sharma et al.,
2009). Both pP23 and pRzP23 plasmids contain sequences for the
50NTR, the P23 coding region which encodes the replication
proteins, the 30NTR and associated poly(A) tail. CVB3 P23 RNA
transcribed from the pP23 plasmid contains two non-viral G
residues at the 50 end which supports only () strand RNA
synthesis. In contrast, CVB3 RzP23 RNA transcribed from the
pRzP23 plasmid contains a 50 hammerhead ribozyme (Rz) which
upon cleavage generates an authentic 50 terminus which supports
both () and (þ) strand synthesis.
Fig. 7. Docking interactions of PV1 3Dpol with full-length VPg and amiloride. (A) A surface representation of 3Dpol is shown in light gray. VPg and amiloride are shown in
green cartoon view and orange stick view, respectively. The sites in 3Dpol that correspond to the VPg interacting residues are colored cyan and the amiloride interacting sites
are colored light orange. The sites that are common for both ligands are colored pale yellow. The two amiloride binding sites in 3Dpol are labeled ‘A’ and ‘B’. The UMP-linkage
site, Y3, in the N-terminus of VPg is also shown in stick view. (B) Model showing hydrogen bond interactions (dashed black lines) between VPg (green Cα) and 3Dpol (light
gray Cα). The UMP-linkage site, Y3, and amino acid side chains involved in hydrogen bond interactions are also shown in the model. (C) Model showing the hydrogen bond
interactions between amiloride (orange) and 3Dpol (light gray Cα). ‘A’ and ‘B’ are the two amiloride binding sites in 3Dpol. Nitrogen atoms are colored in blue, oxygen in red,
chlorine in green and hydrogen in white. The speciﬁc hydrogen bond interactions shown in panels B and C are listed in Table 2. See Supplementary materials for PDB ﬁles of
these ﬁgures.
Table 1
Comparative binding interactions of CVB3 VPg and amiloride to 3Dpol.
Ligand 3Dpol
H-Bond
3Dpol van der Waals
VPg
Q22 K167 K61, R163, S219, P222, Y234, S235, W369,
Y378, F379, L388, V389, V392, P394, H424K20 K360
Q18 K396
R17 D397
V13, P14 R380
K10 N425
Q9 E383
N8 T370, A381
T4 F387
G1 F462
Amiloride
‘A’ D382, H390, E427 A381, F387
‘B’ F379, P386 P222, V223, W369, T370, R380, A381
Bold residues indicate a common binding motif between VPg and amiloride on
3Dpol.
S.A. Ogram et al. / Virology 464-465 (2014) 87–9794
Poliovirus (PV1) cDNA clones
A previously described cDNA clone of the Mahoney strain of
type I poliovirus, designated pT7-PV1(A)80 (Barton et al., 2001),
was used as the parent clone for the constructs used in this study.
(i) PV1 pP23 is a previously described construct with a deletion of
the P1 capsid coding region (Jurgens and Flanegan, 2003). PV1 P23
RNA transcribed from pP23 plasmid expresses all the replication
proteins from the P2 and P3 regions of the viral genome and
functions as an RNA replicon. PV1 P23 RNA contains two non-viral
G residues at the 50 end which supports only () strand RNA
synthesis. (ii) PV1 pRzP23 was generated using PV1 pP23 plasmid
by inserting a hammerhead ribozyme (Rz) downstream of the T7
promoter. PV1 RzP23 RNA transcribed from the pRzP23 plasmid
contains a 50 hammerhead ribozyme (Rz) which upon cleavage
generates an authentic 50 terminus which supports both () and
(þ) strand synthesis (Morasco et al., 2003; Sharma et al., 2005;
Spear et al., 2008).
RNA transcript preparation
The plasmid DNAs described above were linearized by diges-
tion with a restriction enzyme, Mlu1. in vitro transcription was
performed in a 100 ml transcription reaction mixture containing
bacteriophage T7 RNA polymerase and 1 mM of each nucleoside
triphosphate (NTP) (Barton et al., 1996). For PV1 RzP23 transcript
RNA preparation, 0.4 mM of each NTP was added. The 5X tran-
scription buffer contained 200 mM Tris–HCl (pH 7.9), 30 mM
MgCl2 and 10 mM spermidine. For CVB3 P23 and RzP23 transcript
RNAs preparation an additional 4 mM MgCl2 was added. After 2 h
incubation at 37 1C, 0.5% SDS buffer [10 mM Tris–HCl (pH 7.5),
100 mm NaCl, 1 mm EDTA, 0.5% sodium dodecyl sulfate] was
added, and the reaction was extracted three times with phenol–
chloroform–isoamylalcohol followed by three extractions with
chloroform–isoamylalcohol (Barton et al., 1996; Sharma et al.,
2009). Transcript RNA was precipitated in three volumes of
ethanol and puriﬁed by chromatography on a Sephadex G-50 gel
ﬁltration column.
HeLa S10 translation–replication reactions
HeLa S10 extracts and HeLa translation initiation factors were
prepared as previously described (Barton et al., 1996). HeLa S10
translation–replication reactions contained 50% HeLa S10 extract,
20% HeLa translation initiation factors, 1X nucleotide reaction mix
(1 mM ATP, 0.25 mM GTP, 0.25 mM UTP, 60 mM Potassium Acet-
ate, 15.5 mM HEPES–KOH [pH 7.4], 30 mM creatine phosphate,
0.4 mg/ml creatine kinase). CVB3 and PV1 transcript RNAs (5 μg)
were added to 100 μl of HeLa S10 translation–replication reactions
containing 3 mM and 2 mM guanidine hydrochloride (guanidine–
HCl), respectively, and reactions were incubated at 34 1C for 3 h.
To conﬁrm that equivalent levels of proteins were synthesized
in each reaction, a 10 ml aliquot of each reaction was removed,
[35S]-Met added and the reactions were incubated at 34 1C for 3 h.
The amount of labeled viral proteins synthesized in the reactions
was measured by TCA precipitation as previously described
(Barton et al., 1996).
Analysis of viral RNA synthesis in PIRCs
RNA replication was measured in preinitiation-replication com-
plexes (PIRCs) isolated from HeLa S10 translation–replication
reactions containing the indicated transcript RNAs and guani-
dine–HCl. The reactions were incubated at 34 1C for 3 h. PIRCs
were isolated by centrifugation and were resuspended in a
replication buffer containing [α-32P]CTP and 100 μg/ml of puro-
mycin was added as previously described (Barton et al., 2001;
Sharma et al., 2005, 2009; Spear et al., 2008). Indicated concen-
trations of amiloride (purchased from Sigma-Aldrich) were added
to PIRCs and reactions were incubated at 37 1C for 1 h. The
resulting 32P-labeled product RNA was analyzed by denaturing
CH3HgOH–1% agarose gel electrophoresis (Barton et al., 1996).
In these denaturing gels, the RNA structure is completely dis-
rupted, including RI and RF RNA, and the labeled product RNA runs
as a single band in these gels. Equivalent loading of RNA was
conﬁrmed by ethidium bromide (Et-Br) staining of the gel to
visualize the 28S and 18S rRNAs. The labeled product RNA
synthesized in each reaction was detected by autoradiography
and quantitated as PhosphorImager units (PI units) using a
PhosphorImager (Molecular Dynamics). The PI units were used
to calculate the percentage of amiloride inhibition. The 50%
inhibitory concentration (IC50) of amiloride was calculated using
the equation Y¼100/(1þ104((log IC50X)nHillSlope)) (GraphPad
Prism). It is important to note that the IC50 values determined for
amiloride inhibition of viral replication are dependent on the assay
conditions used and will vary depending on the enzyme and
substrate concentrations used in the assay.
Analysis of () and (þ) strand synthesis in PIRCs
P23 transcript RNA which contains two additional G residues at
the 50 terminus and supports only () strand synthesis was used
to measure () strand synthesis in PIRCs. (þ) strand synthesis
was measured in PIRCS as previously described (Sharma et al.,
2005, 2009). To do this, PIRCs were isolated from independent
Table 2
Comparative binding interactions of PV1 VPg and amiloride to 3Dpol.
Ligand 3Dpol H-Bond 3Dpol van der Waals
VPg
Q22 K167 K38, R163, S164, S219, P222, V223, F377,
F378, P385, L387, I388, H389, V391, P393,
E396, H423
K20 D358
T18 K395
R17 T372, K375, D358
T15 R379, N424
K10 D381, E382
K9 A380, D381
N8 A380, W368, E369
T4 F386
G1 F461
Amiloride
‘A’ D381, E382, H389, E426 A380, F386
‘B’ F378, R379, P385 P222, W368, E369, R379, A380
Bold residues indicate a common binding motif between VPg and amiloride on
3Dpol.
Table 3
Binding energies of full-length VPg and amiloride to CVB3 and PV 3Dpol.
Ligand CVB3 ΔG
(kcal mol1)
PV1 ΔG
(kcal mol1)
Fold difference
of bindinga
VPg b 7.3 7.8 2.3
Amiloride ‘A’ c 4.7 4.7 1.0
Amiloride ‘B’ c 5.6 5.5 0.8
a The fold difference of binding is calculated using the equation k¼(kT/h)exp
(ΔG/RT) where k is the binding constant (assumed to be equal to the binding
energy), k is the Boltzmann constant, h is Planck's constant, ΔG is the binding
energy (J mol1), R is the gas constant and T is the temperature in Kelvin. The fold
difference is the ratio of k for PV 3Dpol to that of CVB3 3Dpol.
b Binding energies calculated from the webserver PDBePISA (Krissinel and
Henrick, 2007).
c Binding energies calculated from the webserver PEARLS (Lang et al., 2009).
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reactions containing either P23 transcript RNA or RzP23 transcript
RNA. RzP23 RNA contains an authentic 50 terminus generated by
the addition of a hammerhead ribozyme (Rz) upstream of the ﬁrst
viral nucleotide and supports both () and (þ) strand synthesis.
The total amount of (þ) strand RNA synthesized was calculated by
subtracting the amount of () strand RNA synthesized in the P23
RNA containing reaction from the total RNA synthesized in the
RzP23 RNA containing reaction, which includes both () and (þ)
strand RNAs. The ratio of (þ)/() strand synthesis was calculated
by dividing the amount of (þ) strand RNA synthesized by the
amount of () strand RNA synthesized (Sharma et al., 2005, 2009).
Determination of elongation rates during nascent (þ) strand RNA
synthesis
To isolate preformed replication complexes, CVB3 RzP23 RNA
or PV1 RzP23 RNA was added to HeLa S10 translation–replication
reactions in the absence of guanidine–HCl. The reactions were
incubated at 34 1C for 3 h. During this incubation period, normal
replication complexes which contain () strand RNA and nascent
(þ) strand RNA chains are formed. These complexes were isolated
at 3 h and incubated in replication assay buffer containing [α-32P]
CTP in the absence or presence of 0.8 mM amiloride at 37 1C for
5 min. The nascent (þ) strands were elongated into full-length
RNA during this time period (Fig. 4A). Aliquots were removed at 2,
3, 4 and 5 min after incubation and the resulting full-length
32P-labeled product RNA was analyzed by denaturing CH3HgOH–
1% agarose gel electrophoresis (Barton et al., 1996). The amount of
full-length product RNA synthesized at each time point was
quantitated as PhosphorImager units (PI units) and plotted as a
function of time. The elongation rate was determined as the
amount of [α-32P]CMP incorporated per minute (PI units/min).
The mean incorporation rate was calculated in the presence or
absence of the drug.
Analysis of cre-dependent VPgpUpU synthesis in PIRCs
Synthesis of VPgpUpU was measured in reaction mixtures
containing PIRCs. The uridylylation reactions were identical to
those described above for the RNA replication assays, except the
reaction mixtures contained [α-32P]UTP as previously described
(Morasco et al., 2003). The indicated concentrations of amiloride
were added to PIRCs and the reactions were incubated at 37 1C for
1 h. After incubation, the labeled VPgpUpU synthesized in the
reactions was analyzed and quantitated as previously described
(Morasco et al., 2003).
In silico modeling of VPg and binding energy calculations
Full-length models for VPg binding to CVB3 and PV1 3Dpol were
generated utilizing the currently available X-ray crystallographic
coordinates for a fragment of CVB3 VPg (residues 7–15) bound
along the base of the thumb region of CVB3 3Dpol (PDB: 3CDW)
(Gruez et al., 2008). A least-square ﬁt of the Cα backbone of the
X-ray crystallographic structure for an uncomplexed PV1 (PDB:
2ILZ) (Thompson and Peersen, 2004) was performed in Coot
(Emsley and Cowtan, 2004) to establish the binding site of VPg
in the back of 3Dpol. The coordinates for the CVB3 VPg were then
merged into PV1 3Dpol, with any single amino acid differences
between the two VPgs (e.g. Q9K and R12N) made by manual
changes and rotamer selection to correct for any steric clashes. Any
solvent, ligand and ion molecules (excluding the active site Mg2þ
ions) located in the 3Dpol structures were removed prior to model
building. Full-length models of VPg were generated via manual
elongation in Coot (Emsley and Cowtan, 2004) utilizing available
sequence details for each particular viral variant followed by
subsequent rounds of simulated annealing for energy minimiza-
tion and potential electrostatic interactions in DeepView (Guex
and Peitsch, 1997). The interaction energies of VPg binding at this
site in both CVB3 and PV1 3Dpol were calculated via PDBePISA
(Krissinel and Henrick, 2007).
In silico docking of amiloride on 3Dpol and binding energy
calculations
The inhibitor amiloride was docked in the VPg binding site on
the back of the polymerase as well as in the active site of CVB3 and
PV1 3Dpol using the DOCK 6 suite of programs (Lang et al., 2009)
after being prepared for docking in Chimera (Pettersen et al.,
2004). The 3Dpol enzyme was prepared for docking by deleting all
solvent, ligand and ion molecules, but leaving in place Mg2þ ions
coordinated inside of the polymerase active site. Furthermore,
hydrogen atoms along with charges were added to the amino acid
residues utilizing AMBER (ff12SB) forceﬁelds (Case et al., 2014),
assuming a negative charge for Asp and Glu residues, a positive
charge for Lys residues and an overall neutral charge for His
residues. Amiloride was prepared for docking by adding hydrogens
and was set to contain an overall zero charge (Gasteiger calcula-
tion method) using AMBER's Antechamber module. The amiloride
drug was positioned with no predeﬁned bias for binding location
or speciﬁc orientation along the VPg binding site on the back of
3Dpol as well as in the polymerase active site. The drug was
allowed to sample over 5000 conformations around a 10 Å radius
until the energy minimized conformation was obtained. The
interaction energy of amiloride binding to both CVB3 and PV1
3Dpol was calculated via PEARLS (Han et al., 2006).
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